Epidermolysis Bullosa — Research Summary
Printed from RareWays (rareways.com.au) on 10 June 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
The tumor microenvironment of cutaneous squamous cell carcinoma in high-risk patient groups: A scoping review.
Wang Wandong et al. — JID innovations : skin science from molecules to population health (1 May 2026)
https://pubmed.ncbi.nlm.nih.gov/41815791/
- 2.
Developing CRISPR-Based Therapies for Epidermolysis Bullosa: A Comprehensive Review of Current Strategies.
du Rand Alex et al. — Drugs (1 April 2026)
https://pubmed.ncbi.nlm.nih.gov/41731282/
- 3.
Deciphering MAPK dependence in epidermolysis bullosa-associated squamous cell carcinoma: Toward biomarker-guided MEK inhibition.
Qin Jiuyuan et al. — The Journal of investigative dermatology (1 April 2026)
https://pubmed.ncbi.nlm.nih.gov/41718523/
- 4.
Meta-Analysis of Pain Management in Epidermolysis Bullosa.
Puttinger Christian et al. — The British journal of dermatology (23 March 2026)
https://pubmed.ncbi.nlm.nih.gov/41866785/
- 5.
Innovative Impression Technique for Microstomia Induced by Epidermolysis Bullosa
Rokhssi H et al. (23 March 2026)
https://europepmc.org/search?query=Innovative%20Impression%20Technique%20for%20Microstomia%20In
Clinical Trials — Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials.
- 1.
An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)
Recruiting — Phase 2 — TWi Biotechnology, Inc.
https://clinicaltrials.gov/study/NCT06073132
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Epidermolysis Bullosa
Epidermolysis bullosa is a group of rare genetic conditions that cause extremely fragile skin that blisters and tears easily. It affects the proteins that anchor skin layers together. Severity ranges from mild to life-threatening. Gene therapy and advanced wound care are transforming treatment.
Most Recent Research
Cutaneous squamous cell carcinoma (cSCC) is a prevalent skin cancer in the general population that poses so far unresolved challenges in high-risk groups such as organ transplant recipients and individuals with recessive dystrophic epidermolysis bullosa. Although most cases of cSCC respond well to standard treatments, these 2 groups often face more aggressive disease, characterized by higher rates of metastasis and cancer-specific mortality. The tumor microenvironment plays a pivotal role in cSCC progression, influencing tumor growth, immune evasion, and therapy response. Therefore, this scoping review aims to systematically investigate how the tumor microenvironment in these high-risk cSCC differs from that of sporadic cSCC, highlight shared tumorigenic mechanisms, and identify knowledge gaps for future research. Specifically, we review immune cell infiltration, epithelial-mesenchymal transition, extracellular matrix remodeling, and related biomarkers, while also exploring potential therapeutic targets. It is surmised that both organ transplant recipients cSCC and recessive dystrophic epidermolysis bullosa cSCC may exhibit a permissive tumor microenvironment, potentially characterized by immune dysfunction and enhanced TGFβ signaling, contributing to tumor aggressiveness. Notably, organ transplant recipients cSCC primarily demonstrates immune exhaustion, whereas recessive dystrophic epidermolysis bullosa cSCC is driven by chronic tissue damage with concomitant extracellular matrix remodeling. A better understanding of tumor microenvironment features in these high-risk cSCC may help develop novel targeted therapies to improve patient outcomes.
Common Questions
What is Epidermolysis Bullosa?
Epidermolysis bullosa is a group of rare genetic conditions that cause extremely fragile skin that blisters and tears easily. It affects the proteins that anchor skin layers together. Severity ranges from mild to life-threatening. Gene therapy and advanced wound care are transforming treatment.
How many clinical trials are available for Epidermolysis Bullosa?
RareWays currently indexes 103 clinical trials for Epidermolysis Bullosa, of which 22 are actively recruiting. Trial availability changes as new studies are registered — check the trials tab for current status.
Where does the research data for Epidermolysis Bullosa come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is updated regularly by Rocky, RareWays' automated research engine. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Epidermolysis Bullosa.
No spam. Unsubscribe any time. Not medical advice.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.